Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | HPGD | P15428 | 6/20 | 0.56 |
| ▸ | GLA | P06280 | 6/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.56 |
| ▸ | DRD1 | P21728 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11570772 | 0.94 | KDM4E (0.56) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| SCHEMBL11574238 | 0.92 | KDM4E (0.56) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| SCHEMBL11570132 | 0.85 | KDM4E (0.57) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| SCHEMBL11248049 | 0.85 | KDM4E (0.39) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| SCHEMBL11568720 | 0.83 | KDM4E (0.55) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| SCHEMBL11240874 | 0.82 | ADRA1D (0.60) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| SCHEMBL11241887 | 0.78 | KDM4E (0.40) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| SCHEMBL7787706 | 0.75 | KDM4E (0.73) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| SCHEMBL14369110 | 0.75 | ADRA1A (0.70) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| SCHEMBL7794600 | 0.74 | ADRA1A (0.64) | KDM4EALDH1A1HPGDGLAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0004389-A2 | 4-Amino-6,7-dimethoxy quinazoline derivatives, process for their preparation, their use and a pharmaceutical composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1979-10-03 | — | — | EP | claimed |
| US-7820817-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100105693-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | US | disclosed |
| EP-1753429-A1 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-26 | — | — | US | disclosed |
| WO-2005117883-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-0004389-A2 | 4-Amino-6,7-dimethoxy quinazoline derivatives, process for their preparation, their use and a pharmaceutical composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1979-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105693-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | KDM4E 2719/4885ALDH1A1 2741/4885HPGD 1606/4885 |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | ACHE, CHRM5, CHRM3 | KDM4E 2477/4885ALDH1A1 680/4885HPGD 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.